SCHEMBL15020484

SCHEMBL15020484

CCCCc1n[nH]c(N)c1-c1ccc(C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.43
SMN1; SMN2 Q16637 3/20 0.41
TSHR P16473 2/20 0.41
TP53 P04637 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 1/20 0.41
HEXA P06865 1/20 0.41
HEXB P07686 1/20 0.41
GAA P10253 4/20 0.38
ALDH1A1 P00352 4/20 0.38
LMNA P02545 2/20 0.38
MAPK1 P28482 1/20 0.38
MAPT P10636 1/20 0.38
GCGR P47871 1/20 0.37
MLYCD O95822 1/20 0.37
TLR8 Q9NR97 1/20 0.37
DHFR P00374 1/20 0.37
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27909019 0.85 RAB9A (0.46) DPP4SMN1; SMN2TSHRTP53NPC1
SCHEMBL15020561 0.78 HEXA (0.40) SMN1; SMN2NPC1RAB9AHEXAHEXB
SCHEMBL15042191 0.77 SMN1; SMN2 (0.39) SMN1; SMN2TP53NPC1RAB9AHEXA
SCHEMBL7323862 0.73 GAA (0.45) SMN1; SMN2TSHRTP53NPC1RAB9A
SCHEMBL842957 0.73 SMN1; SMN2 (0.47) SMN1; SMN2NPC1HEXAHEXBGAA
SCHEMBL12368249 0.73 HEXA (0.72) SMN1; SMN2TP53HEXAHEXBALDH1A1
SCHEMBL17500332 0.72 MAPT (0.41) SMN1; SMN2TSHRGAAALDH1A1LMNA
SCHEMBL14782532 0.71 GAA (0.46) SMN1; SMN2TSHRTP53NPC1RAB9A
SCHEMBL17355075 0.70 KDM4E (0.46) SMN1; SMN2TSHRTP53RAB9AHEXA
SCHEMBL13516192 0.69 DHFR (0.51) HEXAHEXBALDH1A1LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8883764-B1 Formylpyrrole-based heterocycles for nucleic acid attachment to supports ILLUMINA, INC. (US) 2014-11-11 US disclosed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 EP disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 DPP4 2407/4885SMN1; SMN2 4424/4885TSHR 2409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.